Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 11, 2022

SELL
$10.37 - $12.73 $7.61 Million - $9.35 Million
-734,300 Closed
0 $0
Q4 2021

Jan 10, 2022

SELL
$10.21 - $15.27 $219,351 - $328,060
-21,484 Reduced 2.84%
734,300 $8.25 Million
Q3 2021

Oct 21, 2021

BUY
$14.07 - $17.3 $10.6 Million - $13.1 Million
755,784 New
755,784 $11 Million
Q1 2021

Apr 15, 2021

SELL
$15.15 - $19.78 $190,783 - $249,089
-12,593 Closed
0 $0
Q4 2020

Jan 14, 2021

SELL
$16.86 - $19.67 $103,874 - $121,186
-6,161 Reduced 32.85%
12,593 $232,000
Q3 2020

Oct 08, 2020

SELL
$15.4 - $20.16 $5.37 Million - $7.02 Million
-348,430 Reduced 94.89%
18,754 $325,000
Q2 2020

Aug 14, 2020

SELL
$18.24 - $21.45 $280,312 - $329,643
-15,368 Reduced 4.02%
367,184 $6.7 Million
Q1 2020

Apr 28, 2020

SELL
$16.28 - $25.63 $97,077 - $152,831
-5,963 Reduced 1.53%
382,552 $7.7 Million
Q4 2019

Feb 06, 2020

BUY
$19.57 - $23.52 $142,528 - $171,296
7,283 Added 1.91%
388,515 $9.05 Million
Q3 2019

Oct 09, 2019

SELL
$19.85 - $22.76 $100,718 - $115,484
-5,074 Reduced 1.31%
381,232 $7.64 Million
Q2 2019

Jul 09, 2019

SELL
$17.59 - $21.1 $37,748 - $45,280
-2,146 Reduced 0.55%
386,306 $8.15 Million
Q1 2019

May 02, 2019

BUY
$18.01 - $20.11 $50,662 - $56,569
2,813 Added 0.73%
388,452 $7.81 Million
Q4 2018

Jan 31, 2019

SELL
$17.44 - $21.53 $11,527 - $14,231
-661 Reduced 0.17%
385,639 $7.08 Million
Q3 2018

Nov 08, 2018

BUY
$19.97 - $21.96 $313,908 - $345,189
15,719 Added 4.24%
386,300 $8.26 Million
Q2 2018

Jul 31, 2018

BUY
$20.16 - $24.68 $7.47 Million - $9.15 Million
370,581 New
370,581 $7.97 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.31B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Crossmark Global Holdings, Inc. Portfolio

Follow Crossmark Global Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.